Skip to main content

Publications

Found 66 results
Author [ Title(Desc)] Year
Filters: Keyword is Pregnancy and Author is Laura A Magee  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
3
Magee LA, von Dadelszen P, Asztalos E, Ross S, Rey E. 34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481.  (706.24 KB)
C
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76.  (803.67 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159.  (476.19 KB)
Magee LA, Synnes A, von Dadelszen P, Hutfield A, Chanoine J-P, Côté A-M, et al.. CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertens. 2018;14:15-22.  (1011.52 KB)
Firoz T, Vidler M, Makanga P, Boene H, Chiaú R, Sevene E, et al.. Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reprod Health. 2016;13(Suppl 2):112.  (1019.85 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41.  (144.71 KB)
Ahmed R, Gafni A, Hutton E, Hu Z, Pullenayegum E, von Dadelszen P, et al.. The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55.  (470.91 KB)
M
De Silva D, Sawchuck D, von Dadelszen P, Basso M, Synnes A, Liston R, et al.. Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87.  (362.1 KB)
Bickford C, Magee LA, Mitton C, Kruse M, Synnes A, Sawchuck D, et al.. Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527.  (2 MB)
Teela K, De Silva D, Chapman K, Synnes A, Sawchuck D, Basso M, et al.. Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347.  (549.75 KB)
De Silva D, Synnes A, von Dadelszen P, Lee T, Bone J, Magee LA. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. Implement Sci. 2018;13(1):8.  (1.89 MB)
Gordon R, Magee LA, Payne BA, Firoz T, Sawchuck D, Tu D, et al.. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163.  (1.42 MB)
Bellad M, Vidler M, Honnungar N, A M, Ramadurg U, Charanthimath U, et al.. Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623.  (2.12 MB)
von Dadelszen P, Magee LA, Payne BA, Dunsmuir D, Drebit S, Dumont G, et al.. Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5.  (662.6 KB)
Aarvold A, Ryan H, Magee LA, von Dadelszen P, Fjell C, Walley K. Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57.  (910.16 KB)
P
Payne BA, Hodgson S, Hutcheon J, Joseph KS, Li J, Lee T, et al.. Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8.  (85.31 KB)
Lalani S, Firoz T, Magee LA, Sawchuck D, Payne BA, Gordon R, et al.. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223.  (529.81 KB)
Firoz T, Magee LA, Payne BA, Menzies J, von Dadelszen P. The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81.  (233.18 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Payne BA, Magee LA, Côté A-M, Hutcheon J, Li J, Kyle PM, et al.. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597.  (292.91 KB)
Benton S, McCowan L, Heazell AEP, Grynspan D, Hutcheon J, Senger C, et al.. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.  (475.29 KB)
Ukah V, Hutcheon J, Payne BA, Haslam M, Vatish M, Ansermino JM, et al.. Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237.  (986.49 KB)
Akkermans J, Payne BA, von Dadelszen P, Groen H, de Vries J, Magee LA, et al.. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62.  (317.15 KB)
Ukah V, De Silva D, Payne BA, Magee LA, Hutcheon J, Brown H, et al.. Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123.  (501.41 KB)
von Dadelszen P, Payne BA, Li J, Ansermino JM, F Pipkin B, Côté A-M, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27.  (201.46 KB)
Mol B, Roberts C, Thangaratinam S, Magee LA, de Groot C, Hofmeyr J. Pre-eclampsia. Lancet. 2016;387(10022):999-1011.  (128.83 KB)
von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454.  (486.35 KB)
von Dadelszen P, Firoz T, Donnay F, Gordon R, Hofmeyr J, Lalani S, et al.. Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.  (322.96 KB)

Pages